|1.||Johnson, Kirk W: 5 articles (04/2014 - 07/2007)|
|2.||Watkins, Linda R: 4 articles (04/2014 - 07/2007)|
|3.||Johnson, Kirk: 2 articles (10/2015 - 06/2010)|
|4.||Hutchinson, Mark R: 2 articles (10/2015 - 07/2007)|
|5.||Rodgers, Krista M: 2 articles (03/2014 - 07/2012)|
|6.||Barth, Daniel S: 2 articles (03/2014 - 07/2012)|
|7.||Bercum, Florencia M: 2 articles (03/2014 - 07/2012)|
|8.||Inoue, Nobuhiro: 2 articles (01/2014 - 01/2008)|
|9.||Harada, Mikio: 2 articles (01/2014 - 01/2008)|
|10.||Hodsdon, Michael E: 2 articles (11/2012 - 06/2010)|
01/01/1992 - "These results suggest that ibudilast would be an effective agent for improving nonspecific airway hypersensitivity in asthmatics."
04/01/1984 - "KC-404 was shown to be effective also on type III allergic reaction."
02/10/2012 - "Ibudilast ameliorated hindpaw hypersensitivity in both SCI and CCI rats, whereas vehicle treatment had no effect. "
02/10/2012 - "Rats were treated with either ibudilast (10 mg/kg IP) or vehicle (2 mL/kg) during the period of robust and steady hindpaw hypersensitivity for each model--CCI rats were treated 14-16 days post-surgery, and SCI rats were treated 30-32 days post-surgery--and tested daily. "
01/01/2001 - "These clinical applications are based on the properties of ibudilast that inhibit platelet aggregation, improve cerebral blood flow and attenuate allergic reactions. "
|2.||Neuralgia (Stump Neuralgia)
02/10/2012 - "Ibudilast could be useful for the treatment of neuropathic pain of central as well as peripheral origin."
04/01/2012 - "Inhibition of TLR4 has shown some biological effects in neuropathic pain models and ibudilast (the TLR4 pathway-inhibiting agent) has been approved for for phase 2 clinical trials. "
07/01/2007 - "Thus ibudilast may improve opioid efficacy and is a promising therapeutic candidate for neuropathic pain, with a novel mechanism of action."
07/01/2007 - "As glial cell activation is considered to crucially contribute to neuropathic pain as well as opioid dependence and withdrawal, the authors conceived that ibudilast may be useful for treating these conditions. "
10/01/2015 - "Preclinically, ibudilast attenuates glial activation and is able to reduce neuropathic pain and markers of substance dependence. "
01/01/2008 - "At 6 months after the start of ibudilast therapy, all patients reported the resolution of dizziness; of the 6 patients with depression at entry, all experienced significant improvement. "
01/01/2014 - "Their at-rest CBF was measured at entry into the study and approximately 3 months after the start of ibudilast therapy when all patients reported the resolution of dizziness. "
01/01/2008 - "In patients treated with ibudilast, the amelioration of dizziness and depression was accompanied by a CBF increase in the right frontal and occipital cortices. "
01/01/2008 - "In these patients, ibudilast (CAS 50847-11-5) reportedly ameliorated dizziness. "
01/01/2014 - "Effect of ibudilast on the reciprocal inhibitory visual-vestibular interaction closely related to dizziness after cerebral ischemia."
01/11/2012 - "An intravenous administration of ibudilast attenuated the size of cerebral infarction in a dose-dependent manner, with the most significant reduction achieved at the dose of 10mg/kg. Ibudilast induced a significant reduction in infarct size when administered 30min before MCAO or 0-2h after reperfusion, with the largest reduction observed at 30min before MCAO and 1h after reperfusion. "
06/01/1985 - "[Effect of KC-404 on experimental cerebral infarction in rats]."
02/01/1993 - "Consecutive brain Tc-99m HMPAO studies before and after a cerebral vasodilator, Ibudilast, administration were performed within 5 hours on 10 patients with cerebral infarction at chronic state. "
01/11/2012 - "Ibudilast significantly attenuated brain edema formation, cerebral atrophy and apoptosis of nerve cells preferentially in the cortical penumbra area, and also significantly reduced mortality and improved neurological outcomes. "
06/01/2015 - "Clinical trial experience to date in PMS has been negative with anti-inflammatory medications used in relapsing MS. Simvastatin was recently tested in a phase II trial and showed a 43% reduction of annualized atrophy progression in secondary progressive MS. Ongoing PMS trials are currently being conducted with the phosphodiesterase inhibitor ibudilast, S1P modulator siponimod and anti-B-cell therapy ocrelizumab. "
01/11/2012 - "We used a rat model of transient focal cerebral ischemia using middle cerebral artery occlusion (MCAO) and reperfusion, and explored the effects of ibudilast on infarction size, brain edema, atrophy, and nerve cell death. "
|2.||Cromolyn Sodium (Cromoglicic Acid)
|5.||Technetium Tc 99m Exametazime (Ceretec)
|8.||Complement System Proteins (Complement)
|10.||Bronchodilator Agents (Bronchodilators)
|1.||Drug Therapy (Chemotherapy)
|4.||Hydrophilic Contact Lenses (Hydrophilic Contact Lens)